Apolipoprotein M in patients with chronic kidney disease

Plasma apolipoprotein M (APOM) is bound to HDL-particles and has anti-atherogenic effects. The present study explored whether plasma APOM is reduced in patients with chronic kidney disease (CKD), and associated with cardiovascular disease (CVD). In addition, we tested the hypothesis that the excreti...

Full description

Saved in:
Bibliographic Details
Published in:Atherosclerosis 2018-08, Vol.275, p.304-311
Main Authors: Sørensen, Ida MH, Bertelsen, Marianne, Freese, Ellen, Lindhard, Kristine, Ullum, Henrik, Feldt-Rasmussen, Bo, Nielsen, Lars Bo, Christoffersen, Christina, Bro, Susanne
Format: Article
Language:English
Subjects:
Cardiovascular risk
Chronic kidney disease
HDL cholesterol
LDL-cholesterol
Plasma apolipoprotein M
Urine apolipoprotein M sphingosine-1-phosphate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Plasma apolipoprotein M (APOM) is bound to HDL-particles and has anti-atherogenic effects. The present study explored whether plasma APOM is reduced in patients with chronic kidney disease (CKD), and associated with cardiovascular disease (CVD). In addition, we tested the hypothesis that the excretion of APOM into the urine is increased in patients with kidney disease. Plasma samples were collected from a cohort of patients with CKD stages 1 to 5D (N = 409) and controls (N = 35). Urine was collected from 47 subjects. Plasma APOM was measured with sandwich ELISA and urine APOM with competitive ELISA. Plasma APOM levels were reduced in patients with CKD stages 3-5D as compared to patients with CKD stages 1 + 2 and controls (p 
ISSN:0021-9150
1879-1484
DOI:10.1016/j.atherosclerosis.2018.06.815